Scottish drug delivery device developer 1nhaler has successfully raised £2 million to propel the development of its revolutionary single-use dry powder inhaler (DPI). Notable contributors to the funding include Dr. Yusuf Hamied, British Business Investments (BBI), and seed investors.
1nhaler, founded in 2017 by Don Smith and Lisa McMyn, is poised to transform the landscape of inhaled medicine delivery. The company’s innovative approach aims to address limitations related to user accessibility, cost, performance, and environmental impact, commonly associated with existing inhaler options.
The unique selling point of 1nhaler’s solution lies in its sustainable DPI, constructed from cardboard and boasting dimensions equivalent to a credit card. This discreet platform integrates a breathable membrane, customizable for the delivery of individual drugs to patients. The funding injection of £2 million positions 1nhaler to collaborate with global partners, facilitating the introduction of both new and existing drugs to patients in a more efficient and cost-effective manner.
Helen Muirhead, Chief Scientific Officer at 1nhaler, brings decades of experience to the team, having previously held responsibilities for GSK’s blockbuster respiratory portfolio, including the Diskus and Ellipta inhalers.
Lisa McMyn, CEO and Co-founder of 1nhaler, expressed optimism about the potential impact of their DPI, stating, “Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionizing the delivery of critical drugs without the cost and environmental impact of existing devices.”
Archangels, a key player in the funding round, brings both life sciences expertise and a patient capital approach to the table. Dr. Sarah Hardy, Director and Head of New Investments at Archangels, commended 1nhaler, saying, “Don, Lisa, and the team at 1nhaler have developed a truly innovative technology platform with a clear route to market and an opportunity to positively disrupt the status quo of single-dose medicine delivery.”
As 1nhaler moves forward, backed by a diverse range of investors and industry experts, the company aims to increase the availability of life-saving drugs affordably and sustainably. This latest funding round marks a significant step in realizing their vision of transforming drug delivery through their groundbreaking cardboard-based inhaler.